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Abstract
Background: The present study investigates the effects of high external calcium concentration ([Ca2+]o) and the
calcimimetic NPS R-467, a known calcium-sensing receptor (CaSR) agonist, on growth/proliferation of two equine size-
sieved umbilical cord matrix mesenchymal stem cell (eUCM-MSC) lines. The involvement of CaSR on observed cell response
was analyzed at both the mRNA and protein level.
Methodology/Principal Findings: A large (.8 mm in diameter) and a small (,8 mm) cell line were cultured in medium
containing: 1) low [Ca2+]o (0.37 mM); 2) high [Ca
2+]o (2.87 mM); 3) NPS R-467 (3 mM) in presence of high [Ca
2+]o and 4) the
CaSR antagonist NPS 2390 (10 mM for 30 min.) followed by incubation in presence of NPS R-467 in medium with high
[Ca2+]o. Growth/proliferation rates were compared between groups. In large cells, the addition of NPS R-467 significantly
increased cell growth whereas increasing [Ca2+]o was not effective in this cell line. In small cells, both higher [Ca
2+]o and NPS
R-467 increased cell growth. In both cell lines, preincubation with the CaSR antagonist NPS 2390 significantly inhibited the
agonistic effect of NPS R-467. In both cell lines, increased [Ca2+]o and/or NPS R-467 reduced doubling time values.Treatment
with NPS R-467 down-regulated CaSR mRNA expression in both cell lines. In large cells, NPS R-467 reduced CaSR labeling in
the cytosol and increased it at cortical level.
Conclusions/Significance: In conclusion, calcium and the calcimimetic NPS R-467 reduce CaSR mRNA expression and
stimulate cell growth/proliferation in eUCM-MSC. Their use as components of media for eUCM-MSC culture could be
beneficial to obtain enough cells for down-stream purposes.
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Introduction
Mesenchymal stem cells (MSCs) are undifferentiated cells able
to self-renew, that have a high proliferative capacity and grow as
adherent cells [1]. Several reports suggest that MSCs are able to
differentiate into various cell types, including chondrocytes,
osteocytes, adipocytes, myocytes, cardiomyocytes and neurons
[2,3]. MSCs can be isolated from different adult tissues, such as
bone marrow (BM), adipose tissue, dental pulp; in extraembryonic
tissues, such as placenta and umbilical cord (UC) and from a
variety of fetal tissues, such as spleen, lung, pancreas, liver,
kidneys, amniotic fluid [1,4–6]. Recently, several groups reported
success, both in humans and in large animal models, in isolating
and establishing MSCs cultures from fetal adnexa such as amniotic
membrane, amniotic fluid or UC (human:[7,8], pigs [9], horses
[10–15] and dogs [16–18]. The process through which these cells
can be obtained is non-invasive, painless and without harm for the
mother or the infant [1,10,11].
Several studies have been performed to determine the possibility
to obtain MSCs from UC matrix (UCM) or stroma, namely
Wharton’s jelly, the primitive connective tissue of UC [1,5,8].
Wharton’s jelly in UC surrounds a set of two arteries and one vein
and is composed by a mucous connective tissue rich in
proteoglycans, mainly hyaluronic acid, and specialized fibroblast-
like cells [3]. By using Wharton’s jelly, a significantly greater
number of MSCs can be isolated than in other adult or fetal tissue
such as BM or UC blood [7]. MSCs have been isolated from three
regions of Wharton’s jelly: the perivascular zone, the intervascular
zone and the subamnion. At the present time, it is unknown
whether MSCs isolated from these different compartments could
represent different cell populations [5]. Wharton’s jelly MSCs do
not present an univocal phenotype, but they show markers that are
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present on other cellular lineages. Immunophenotyping by flow
cytometry revealed that these cells are positive for specific MSC
markers such as CD73, CD90, CD105 [3,19–21] and they are
negative for the hematopoietic line markers such as CD34 and
CD45 [1,3,19–22]. These cells are also negative for the human
leukocyte antigen HLA-DR [1,3,19,20,22,23] thus suggesting a
potential role as a human allogenic cell source for cell-based
therapies. Many works have reported that Wharton’s jelly MSCs
can be induced to differentiate in vitro into adipogenic, osteogenic
and chondrogenic lineages [1,3,8,19–22,24–26], cardiomyocyte
[3,8,24,27] and neural-like cells [3,8,20,22,28,29].
In the past few years, attention has been drawn to MSCs
because of their potential use in cell therapy and regenerative
medicine in several clinical fields. In parallel with advancing of
studies on MSC, the urgency of establishing suitable animal
models that could allow researchers to study the properties of
MSCs and their use in different pathological conditions has
become more evident. Stem cell and tissue engineering research in
the horse has exciting comparative and equine-specific perspec-
tives that most likely will benefit the health of horses and humans
[30]. Recently, first reports on the possibility to isolate, to
characterize and to grow in vitro equine umbilical cord matrix
mesenchymal stem cells (eUCM-MSCs) have appeared in the
literature [10–13,31]. Equine UCM is a source of primitive,
mesenchymal stem cells that can be cultured, cryogenically
preserved and differentiated in adipocytes, chondrocytes, osteo-
blasts and in cells with a morphology typical of neurons with axon-
and dendrite-like processes [10,11]. These cells showed expression
of the embryonic markers Oct-4, SSEA-4 and c-Myc that is a
regulator of early gene expression and cell cycle progression in a
variety of proliferating cells. Equine UCM-MSCs (eUCM-MSCs)
also expressed a number of antigens associated with pluripotent
adult stem cells, including CD54, CD90, CD105, and CD146.
There was no significant expression of HLA-ABC, HLA1AG, and
MHC II [10]. Cremonesi et al., 2008; [12] showed that eUCM-
MSCs express mRNA for Oct-4 and Sox-2 markers.
Extracellular calcium (Ca2+) is a potent mediator of the
balance between proliferation and differentiation in a number of
different cell types [32,33]. Expression of the G protein-coupled
calcium-sensing receptor (CaSR) has been demonstrated in Ca2+
responsive epithelial and mesenchymal cell types, thus suggesting
a possible mechanism by which Ca2+ could induce changes in
proliferation [33–36].The CaSR plays a key role in the
regulation of whole-body Ca2+ metabolism [32,37,38]. The
molecular identification of CaSR in bovine parathyroid cells by
Brown et al., 1993; [39] opened up the possibility that Ca2+ can
be considered as a first messenger outside cells [39,40]. The
CaSR was originally named for its ability to detect/transduce
subtle but physiologically meaningful changes in extracellular
Ca2+ concentration ([Ca2+]o). However, it responds to many
other bivalent and trivalent cations, to changes in other
physiological parameters such as L-amino acids, polyamines,
ionic strength, pH, and to drugs such as aminoglycosidic
antibiotics, calcimimetics, and calcilytics [32,41]. CaSR-null
mice exhibit loss of feedback control of parathyroid hormone
secretion, hyperparathyroidism, and metabolic bone diseases.
Moreover, inactivating and activating mutations of the receptor
in humans have been shown to induce various disorders of Ca2+
metabolism [41]. CaSR has been reported to be widely
expressed in several mammalian tissues, including tissues that
are not clearly involved in Ca2+ metabolism such as brain, lens
epithelial cells, pituitary gland, bone marrow, peripheral blood,
breast ductal cells, pancreas, keratinocytes, ovarian surface
epithelial cells, parathyroid gland stem cells and the gastrointes-
tinal system [32,33,39,41–43]. CaSR localization in cells that
seem to have no functional relationship with the maintenance of
the whole-body Ca2+ balance has been linked to the regulation
of different cellular processes, such as secretion, chemotaxis,
apoptosis, cell proliferation, differentiation, and ion channel
activity [2,41].
The aim of the present study was to evaluate the effects of
[Ca2+]o and a calcimimetic, NPS R-467 known as a selective
CaSR agonist, on growth/proliferation of two equine size-sieved
UCM-MSC lines. The involvement of the extracellular CaSR on
observed stimulation of growth/proliferation in these cell lines was
investigated by evaluating added compounds on CaSR mRNA
and protein expression.
Results
Experiment 1: Effects of high external calcium
concentration and the calcimimetic NPS R-467 on
growth/proliferation of equine size-sieved UCM-MSCs
Increasing external Ca2+ to 2.5 mM did not affect cell growth,
in the large (Fig. 1A’) cell line, whereas in the small cell line
(Fig. 1B’), it significantly increased cell growth compared with
controls (P,0.05). The addition of NPS R-467, in presence of
2.5 mM exsternal Ca2+, in both cell lines significantly increased
cell growth compared with controls (P,0.001 for both the large
cell line and P,0.05 for the small cell line). In detail, in the growth
study, the large cell line was not stimulated by increased Ca2+ but
it was stimulated by NPS R-467 both earlier (from day 7) and
strongly (P,0.001) (Fig. 1A’). This may lead to the hypothesis that
Ca2+, in this cell line, could have primed the receptor to the effects
of its selective agonist NPS R-467. On the other hand, the small
cell line responded both later (on day 9) and more weakly (P,0.05)
stimulated by both Ca2+ and calcimimetic NPS R-467 (Fig. 1B’).
In both cell lines, preincubation with the CaSR antagonist NPS
2390 inhibited the agonistic effect of NPS R-467.
Additionally, DT evaluation in all examined culture conditions
were performed with the aim to evaluate long term effects of
tested compounds on the eUCM-MSC proliferation rate.
Interestingly, it was observed that, in both cell lines, cell
proliferation rate increased (approximately 3 fold) whenever
extracellular Ca2+ was increased (2.5 mM, 2.5 mM+R-467 and
2.5 mM+2390+R-467). It can be hypothesized that elevating
[Ca2+]o in culture medium is beneficial to increase UCM-MSC
proliferation rate at later passages. DT values were calculated
from P5 to P8 for both, large and small, cell populations. The
stimulatory effects of additional Ca2+ and NPS R-467 on cell
proliferation occurred at P8 in the large cell line and from P7 in
the small cell line. Whenever additional Ca2+ was added, reduced
cell DTs were observed compared with controls (large cell line,
DT values = 5.59, 4.03 and 5.59 for 2.5 mM CaCl2,
2.5 mM+NPS R-467 and 2.5 mM+NPS 2390+NPS R-467
respectively vs 12 in CTRL; small cell line, DT values = 4.03,
5.59 and 2.90 respectively vs 12 in CTRL), thus evidencing a
stimulatory effect of increasing Ca2+ concentration on cell
proliferation of UCM-MSCs.
Experiment 2a: Effects of higher external calcium and the
calcimimetic NPS R-467 on the relative abundance of the
CaSR transcript in equine UCM-MSCs
In the large cell line, the CaSR transcript level decreased in
higher Ca2+- and agonist-treated cells compared with controls. Its
relative abundance was reduced to 2% of the control value in
higher Ca2+-(P,0.001) and to 13% in agonist-treated cells
CaSR in Equine Umbilical Cord Matrix Stem Cells
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(P,0.001). In antagonist-pretreated cells, the CaSR transcript
level increased up to approximately 3 fold compared with agonist-
treated cells (0.38 vs 0.13; P,0.05, Fig. 2A).
In the small cell line, in higher Ca2+-treated cells, the CaSR
transcript level was approximately a quarter of the value observed
in control samples (P,0.001). In this cell line, the relative
abundance of the CaSR transcript was reduced to 72% of control
levels upon agonist treatment (P,0.001; Fig. 2B). In cells pre-
incubated in the presence of the CaSR antagonist NPS 2390,
higher amounts of the CaSR transcript were found (0.97)
compared with those found in agonist-treated cells (0.72;
P,0.05). The relative abundance in antagonist pre-treated cells
was similar to that of controls (reference sample value = 1;
Fig. 2B).
Figure 1. Effects of Ca2+, the calcimimetic NPS R-467 and the CaSR antagonist NPS2390 on eUCM-MSC growth. Cells were plated in 6-
wells plates and treated as described in materials and methods. Effects of increasing doses of extracellular Ca2+ on both, large (A) and small (B), cell
lines. In the large cell line (A’), increasing Ca2+ concentration to 2.5 mM was not effective on cell growth. In the presence of 2.5 mM Ca2+, the allosteric
activator of the CaSR, NPS R-467 (3 mM) significantly increased the cell number/well from day 7th after treatment (P,0.001). In the small cell line (B’),
increasing Ca2+ concentration induced cell growth on day 9th (P,0.05). In the presence of 2.5 mM Ca2+, the allosteric activator of the CaSR, NPS R-467
significantly increased the cell number/well on day 9th (P,0.05). In both cell lines, 30 min preincubation in presence of the CaSR antagonist NPS 2390
(10 mM) significantly inhibited the agonist effect. Results are mean 6 SD of 2 data points. Student’s t Test: a vs b: P,0.05; a vs e: P,0.01; c vs d
P,0.001.
doi:10.1371/journal.pone.0017714.g001
Figure 2. CaSR transcript relative abundance in eUCM-MSCs upon Ca2+- or calcimimetic-induced CaSR stimulation. Quantitative Real
Time RT-PCR analysis of the CaSR transcript in Ca2+ (2.5 mM CaCl2) and calcimimetic-treated (2.5+R-467) equine UCM-MSCs versus controls (CTRL) or
cells pre-incubated with the CaSR antagonist (2.5+2390+R-467). Cells were examined on day 4th after treatments. For each sample, data (mean 6 SD
of three independent experiments in duplicate, CaSR average Ct) were normalized relatively to the abundance of HPRT1 mRNA (endogenous control)
and normalized values were compared among groups. In the large cell line (panel A), CaSR transcription was strongly down-regulated in presence of
additional Ca2+ (2% of control value; vs b: P,0.001) and NPS R-467 (13%; a vs b: P,0.001). In the small cell line (panel B), CaSR transcription was again
down-regulated by additional Ca2+ (25%; a vs b: P,0.001) and NPS R-467 (72%; a vs b: P,0.001) even at a lesser extent. In both cell lines, the CaSR
antagonist NPS 2390 reversed the effects of NPS R-467 (38% and 97%, for the large and the small cell line, respectively; c vs d: P,0.05).
doi:10.1371/journal.pone.0017714.g002
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Experiment 2b: Effects of increased external calcium
concentration and the calcimimetic NPS R-467 on CaSR
protein expression and subcellular localization in equine
UCM-MSCs
The CaSR protein was found to be expressed (green
labeling) in eUCM-MSCs of both cell lines cultured in all
examined conditions. In all samples, marked staining in light
green was seen with an ubiquitous distribution within the
cytoplasm and along the plasma membrane. Interestingly, in
the large cell line, treatments with higher Ca2+ or higher Ca2+
plus the CaSR agonist increased the number of cells showing
marked labeling on the plasma membrane and reduced the rate
of cells showing prevailing CaSR labeling in the cytosol,
compared with controls. In detail, after treatment with higher
Ca2+, the difference approached statistical significance (18/44,
41% vs 8/40, 20%; Chi-square = 3.36) whereas it was
statistically significant (20/40, 50% vs 8/40, 20%; P,0.05) in
cells cultured in the presence of both Ca2+ and CaSR agonist
(Fig. 3A–D). In the small cell line, neither increased Ca2+
concentration nor the addition of CaSR agonist addition had
any effect on CaSR protein localization. Cells showed a round
shape and a vescicular large nucleus (Fig. 3E). No staining was
detected in negative controls (minus primary antibody controls;
Fig. 3F).
Discussion
Kinetic study
After preliminary testing of CaSR expression in eUCM-MSCs
of both cell lines by immunocytochemistry, the first purpose of this
study was to determine whether CaSR activation, by means of
increased Ca2+ or calcimimetic NPS R-467 addition, could
stimulate growth/proliferation of eUCM-MSCs. In both cell lines,
cell growth/proliferation was stimulated by Ca2+ or calcimimetic
NPS R-467 addition and their effects were reversed by the CaSR
antagonist NPS 2390 even if the two cell lines behaved differently.
Our data are in agreement with previous studies where several
cell systems have been shown to respond differently to Ca2+ or
NPS R-467 treatments in relation to their effects on cell
proliferation which can be stimulated or inhibited to a different
extent [32,44–46].
The calcimimetic NPS R-467 is a phenylalkylamine compound,
able to potentiate the effects of extracellular Ca2+ on CaSR [48–
52] and has been reported to act through the transmembrane
domain of CaSR by increasing the affinity of the receptor for its
cognate G proteins or by enhancing the signal transduction from
the ‘head’ of the CaSR to its intracellular domains [53–55]. Here,
in both examined cell lines we observed that the allosteric activator
of the CaSR NPS R-467 increased cell growth and this effect was
inhibited by adding the CaSR antagonist NPS 2390. These data
provide evidence that the NPS R-467-induced cell growth is a
CaSR-mediated response. Our observations are in agreement with
previous studies in which it was reported that NPS R-467 and the
NPS R-467 precursor, NPS R-568, stimulate cell mitosis
[33,35,44,56–58] and oocyte meiosis [59].
As a confirmation to the observed CaSR-mediated effect on
eUCM-MSC, we tried to revert the stimulatory effect observed in
the presence of NPS R-467 by using a CaSR antagonist, NPS
2390. As previously observed, NPS 2390 is a potent and selective
non-competitive group I metabotropic glutamate receptor
(mGluR) antagonist [60]. In relation to CaSR’s reportedly high
structural homology with mGluR1 [52], NPS 2390 has been used
as CaSR antagonist in previous studies [61,62]. Indeed, in the
present study, the effect of NPS R-467 was significantly reduced
by pre-incubation in the presence of NPS 2390 in both cell lines
even at different time points (from day 7 for the large cell line and
on day 7 and 14 in the small cell line). These data are in
agreement with previous studies reporting effects of NPS 2390 in
reducing intracellular Ca2+ concentration [61,62], cell prolifer-
ation [62] and the rate of oocytes reaching meiotic maturation
[59].
Taken together, our data indicated that CaSR activation may
lead to an increase of growth/proliferation rate in eUCM-
MSCs. However, different responses were obtained in the two
examined cell lines upon treatment with increased [Ca2+]o or
the CaSR agonist NPS R-467. The different response to
treatments between the two examined cell lines suggested that
CaSR could be differentially expressed and activated in these
cell lines.
Figure 3. CaSR protein expression and subcellular localization
in eUCM-MSCs upon Ca2+- or calcimimetic-induced CaSR
stimulation. Detection of CaSR expression in equine UCM-MSCs in
the .8 mm cell line (A, C) and ,8 mm cell line (B, D) by
immunofluorescence with a primary antibody against a 20 amino acid
peptide sequence near the C-terminus of human CaSR and observation
by confocal laser scanning microscopy. In both cell lines, cells showing
CaSR labeling either predominantly evident whitin the cytoplasm (A, B)
or on the plasma membrane (C, D) were present. For each cell, scanning
was conducted with 12 optical series from the top to the botton of the
cell with a step size of 0.45 mm and images were taken to the equatorial
plane. Representative photomicrograph of equine UCM-MSC as
observed after thawing, staining with Hoechst 33258 and observed
under phase contrast microscopy merged with UV light epifluorescence
(E). In this cell, regular round shape morphology and an eccentric
nucleus can be seen. Negative minus primary control (F). Scale bar
represent 20 mm (A, C, E, F) or 10 mm (B, D).
doi:10.1371/journal.pone.0017714.g003
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Effects on CaSR expression
In order to confirm that both the Ca2+ and the calcimimetic
NPS R-467- induced cell proliferation in eUCM-MSCs were
CaSR-mediated responses, the second group of experiments were
aimed at testing whether CaSR expression was modified, at
mRNA and/or protein level, upon treatments. In order to
evaluate modifications preceding cell proliferative responses,
samples were examined on day 4 after treatments. Detection of
CaSR expression was confirmed, both at mRNA and at protein
level, in both cell lines.
In the large cell line (strongly stimulated to proliferate upon
agonist treatment), CaSR transcription was strongly down-
regulated both upon Ca2+ and calcimimetic plus agonist
treatment. In the small cell line (weakly stimulated to proliferate
upon Ca2+ and agonist treatment), CaSR transcription was
significantly down-regulated by Ca2+ and CaSR agonist treatment
even if at lesser extend. At the present time, these findings could be
only interpreted as being related to hypotheses reported in
previous studies. As an example, Roussanne et al. 2001; [65]
reported that an increase in [Ca2+]o stimulates, while the
calcimimetic NPS R-467 inhibits, the in vitro proliferation rate of
parathyroid cells derived from uraemic patients, known to express
reduced CaSR levels. In the attempt to explain these apparent
discrepancies those authors hypothesized that calcium may
regulate cell proliferation by two different pathways: 1) with
predominant growth inhibition in cases of high CaSR expression
or activation, but with prevailing stimulation of proliferation in
cases of low CaSR expression.
In the present study, extracellular Ca2+ and the calcimimetic
NPS R-467 regulated cell proliferation with strong stimulation in
the case of strongly lowered CaSR relative expression (as observed
in the large cell line) but weak stimulation in the case of weakly
lowered relative CaSR abundance (as observed in the small cell
line). There are a relatively few studies available to date on the
relation between CaSR mRNA/protein relative abundance and
cell proliferation. However, most of in vitro studies yielded
different results: to our knowledge, three studies reported increased
CaSR expression upon high Ca2+ in vitro exposure [66–68]; two
other studies found no effect [69–70].
A possible explanation of this cell context-dependent response
might be found in the reports that the CaSR gene has promoter
regions sensitive to both Ca2+ and Vitamin D. Response elements
for the two regions could determine what the answer whether an
‘‘up’’ or a ‘‘down-regulation’’ of CaSR expression [66]. It could be
hypothesized that in a stem cell population, not yet committed to
undergo differentiation (maintained in culture in the absence of
differentiation stimuli), extracellular Ca2+ elevation could either
induce an interaction of the promoter with some elememt specific
to the type of stem cell through a different promoter structure or,
through a still unknown post-translational mechanism of regula-
tion of CaSR by Ca2+ or its mimicks, produce a CaSR down-
regulation and cell growth/proliferation. Further studies are
necessary to fully explore the mechanism of Ca2+-induced CaSR
expression in UCM-MSCs.
In addition, CaSR mRNA, in eUCM-MSCs issuing from the
two cell lines examined in the present study, may be 1) regulated
by different promoters, as reported in other cell systems [64], 2) be
present in two different allelic forms to produce two different
protein isoforms that can be both detected by the antibody used in
the present study; 3) have different signal transduction pathways/
mechanisms that may differentially regulate the response to CaSR
stimulation. These hypotheses could be related to observations by
Roussanne et al., 2001; [65]. Again, the occurrence of post-
translational modifications of the receptor (such as glycosylation,
phosphorylation or ubiquitination, etc) during the process of
differentiation/growth of these two cell lines or the presence of
different protein amounts could be hypothesized.
CaSR protein in eUCM-MSCs was identified and localized
within the cytoplasm and in the cortical region. As previously
observed in other cell systems, the receptor present on the cell
surface could represent the mature form of the receptor whereas
the cytoplasmic CaSR could simply represent the nascent
receptor protein, undergoing post-translational modifications,
even if it cannot be excluded that it could have a distinct
biological function, such as intracellular Ca2+ sensing [71,72].
This dual CaSR staining pattern, cytosolic and on the cell
surface, has been observed in previous studies performed in
osteoblastic cell lines (human, [73]; rat, [63]) as well as in rat
oligodendrocytes [69], rat microglia [57,63], mouse mesangial
cells [62], human and equine cumulus-oocyte complexes and
ovarian granulosa cells [74,59]. In the large cell line treated with
Ca2+ or with Ca2+ plus NPS R-467, CaSR immunostaining
increased at cortical level and was reduced in the cytosol. The
difference approached statistical significance in cells treated with
calcium and was statistically significant (P,0.05) in cells treated
with Ca2+ plus NPS R-467. This finding further supports our
hypothesis that these compounds activate CaSR in eUCM-MSCs
leading to cell CaSR-mediated cell proliferation. Our data are in
agreement with data obtained in a previous study from our unit
in equine cumulus and granulosa cells [59].
Conclusions
In conclusion, we show that CaSR is expressed at mRNA
and protein levels in eUCM-MSCs, and is functionally active
since calcium and the selective CaSR agonist NPS R-467
induced a stimulatory effect on cell growth/proliferation and
this effect was reversed by pre-incubation with the CaSR
antagonist NPS 2390. The CaSR agonist improved cell growth/
proliferation in the presence of physiological [Ca2+]o. In the two
examined cell lines, the CaSR transcript was strongly (large) or
weakly (small) down-regulated on day 4 after treatment, leading
respectively to strong or weak increase in cell growth/
proliferation. In cells showing the stronger proliferative response
(large cell line), treated with Ca2+ plus NPS R-467, CaSR
immunostaining increased at membrane level and was reduced
in the cytosol. Taken together, these data provide a significant
contribution to the knowledge of CaSR expression and
regulation mechanism in UCM-MSC from UC. Observed
differences between analyzed cell lines could be related to
differences in their developmental and functional stage, as
reported by Corradetti et al., 2010 [13] who suggested that in
the perivascular portion of UCM, the large cells are mature
MSC and the smaller ones are recycling stem cells. Increasing
calcium concentration and adding NPS R-467 in culture media
for eUCM-MSC might be beneficial in order to obtain a
desirable result of increasing the cell number and reducing the
time interval necessary to obtain enough cells for downstream
therapeutic purposes.
Materials and Methods
Chemicals
NPS R-467 ((R)-N-(3-phenylpropyl)-a-methyl-3-methoxybenzy-
lamide hydrochloride was a kind gift of Dr. R. Caroppo,
Department of General and Environmental Physiology, Faculty
of Biological Sciences, Via Orabona Bari Italy). NPS 2390
(Quinoxaline-2-carboxilic acid adamantan-1-ylamide) was pur-
chased by Sigma (N 4786), Milan Italy.
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Cell lines
The study was carried out on two homogeneous subpopulations
of eUCM-MSCs both isolated from perivascular Wharton’s jelly
by using a particular culture device: multi-dishes with transwell
inserts of 8 mm pores as described by Corradetti et al., 2010; [13].
Therefore, we have referred to the cells as size-sieved stem cells
separated by their dimension. In this way, two types of adherent
cells appeared after seeding, one larger than 8 mm (namely, large
cell line) and the other smaller than 8 mm in diameter (namely,
small cell line). These two cell lines were previously reported as
positive for MSC markers (CD105, CD44, CD29) and negative for
the emopoietic CD34 marker as assessed by RT-PCR [13].
Culture conditions
Cells were cultured at 38.5uC in a humidified atmosphere (95%)
under 5% CO2 in standard expansion medium consisting of
Dulbecco’s Modified Eagle’s Medium - High Glucose (DMEM)
(Sigma D-5546) supplemented with 10% Fetal Calf Serum (FCS)
(Sigma F3018), 100 U/ml penicillin, 100 mg/ml streptomycin,
0.25 mg/ml amphoterycin solution (Sigma A-5955), 2 mM L-
glutamine (Sigma G-7513) and 10 ng/ml Epidermal Growth
Factor (EGF; Sigma E-9644).
Cell freezing
After trypsin treatment and count, cells of each well were
resuspended in standard medium supplemented with 10% (v/v)
FCS and 10% (v/v) dimethyl sulfoxide (DMSO, Sigma D-5879)
and cryopreserved in cryotubes that were stored at 280uC and
then transferred to cryogenic containers with liquid nitrogen until
molecular and immunofluorescence analysis.
Reverse Transcription PCR
The Cell-to-cDNA II kit (AM1722, Ambion, Monza, Milan,
Italy) was used to produce cDNA. After thawing, cells were
washed in PBS and then heated in Cell Lysis II buffer at 75uC for
109 to release RNA after rupture of the cells and to inactivate
RNases. Next, the cell lysate was treated with DNase I to degrade
genomic DNA (37uC for 159) and after that, DNase was
inactivated by heating to 75uC for 59. Five to 10 mL cell lysate
was added with 4 mL dNTP Mix, 2 mL of random decamers and
carried to 16 mL with nuclease-free water then was heated 3 min
at ,70uC. Next, the remaining RT reagents were added: 2 mL
10X RT Buffer, 1 mL M-MLV Reverse Transcriptase, 1 mL
RNase Inhibitor, mixed gently and centrifuged briefly. For the
minus-RT control, water was added at this time point. Reaction
tubes were incubated at 42uC for 15–60 min, then at 92–95uC for
10 min to inactivate the reverse transcriptase.
Real Time PCR
Real Time PCR was performed by using Real Time TaqMan
technology and analyzed on automated ‘‘StepOne System’’
(Applied Biosystem, Monza, Milan Italy). The CaSR primers
and probe were designed, intron-spanning, using Primer Express
3.0 (Applied Biosystem) on the basis of equine CaSR mRNA
(GenBank accession no. GI255653075) and were as follows: CaSR
Real Time PCR primers: forward primer: 59-CTTGGCA-
GGTCCTGAAGCA-39; reverse primer: 59-TGGTTGTTATA-
CCCCCTGGTC-39; CaSR hybridization probe: 59-CTACGG-
CACCTCAAC-39 (Applied Biosystem). The CaSR hybridization
probe, which binds to PCR products, was labeled with a reporter
dye (6-carboxy-fluorescein, FAM) on the 59 nucleotide and a
quenching dye (MGB, minor groove-binder) with NFQ (non
fluorescent quencher) on the 39 nucleotide where MGB hyper-
stabilized duplexes with complementary DNA. TaqMan equine
Hypoxanthine phosphoribosyltransferase 1 (HPRT1), inventoried
by Applied Biosystem (EC03470220_M1), was used as endogenous
control. Samples were run in duplicates on Microamp fast optical
48-well reaction plate (Applied Biosystem) where twenty-microliters
reactions for each well contained: 10 mL TaqMan gene expression
Master Mix 2X (Applied Biosystem), 1 mL 900 nM Primers,
250 mM Probe, 4 mL cDNA, 5 mL: RNase Free H2O. Cycling
parameters were: 2 min at 50uC, 10 min at 95uC followed by 47
cycles of 15 s at 95uC and 1 min at 60uC. Data were collected by
using the OneStep Software and relative quantification was
performed by using comparative method after determining the Ct
(threshold cycle) values for the reference (HPRT1) and the target
gene (CaSR) in each sample sets, according to the 2-DDCt method as
described by the manufacturer. Changes in mRNA expression levels
were calculated after normalization to HPRT1. The program
calculates the DCt and the DDCt with the formulas below: DCt =
Ct_Mean(HPRT1) - Ct_Mean(CaSR); DDCt = DCt - DCt_Mean,
so that the gene expression level = 22DDCt. Changes in gene
expression were reported as percentage changes relative to controls.
Immunofluorescence
After collection by trypsin digestion, cells of each treatment (as
reported in the Experimental design, see below) were analyzed for
CaSR protein expression as previously reported by Dell’Aquila et
al., 2006; [69] and De Santis et al., 2009; [59] for ovarian cumulus
and granulosa cells. Briefly, cells were seeded on polylisinated
slides and fixed in Aceton (Sigma 20083-044) for 1 h, washed in
100 mM glycine in Phosphate Buffered Saline (PBS), and
incubated for 30 min in 1% (w/v) Bovine Serum Albumin (BSA)
in PBS (PBS-BSA). Cells were then incubated overnight at room
temperature in a 1:2500 dilution of a primary rabbit polyclonal
antibody against a 20 amino acid peptide sequence near the C-
terminus of human CaSR (antiCaSR C0117-15 US Biological,
Swampscott, MA, USA). Cells incubated overnight in PBS-BSA
were used as negative controls (minus primary controls). At the
end of incubation, cells were washed in PBS, then incubated for
2 h at room temperature with a fluorescein isothiocyanate (FITC)-
conjugated rabbit IgG-secondary antibody, diluted 1:200 in PBS
and evaluated by confocal microscopy as described below.
Evaluation of cell morphology, by phase contrast microscopy,
and nuclear chromatin, by epifluorescence microscopy after
2.5 mM Hoechst 33258 (Sigma B-1155) staining (in 3/1 glycer-
ol/PBS solution), were also performed.
Confocal laser scanning microscopy and image analysis
Cells were observed at 6006magnification in oil immersion with
a laser-scanning confocal microscope (C1/TE2000-U Nikon)
equipped with the Argon Ions 488 laser and the 495–519 (B2-A)
nm excitation/emission filter. For each field, scanning was
conducted with 12 optical series from the top to the bottom of
the cell with a step size of 0.45 mm. Parameters related to
fluorescence intensity (x63 objective, zoom =0, 30 mm pinhole
size) were maintained at constant values for all measurements.
Experimental design
Experiment 1: Effects of high external calcium
concentration and the calcimimetic NPS R-467 on growth/
proliferation of equine size-sieved UCM-MSCs. At a
preliminarily level, a dose-response study of the effects of
extracellular Ca2+ on UCM-MSCs was performed in order to
identify the best concentration of Ca2+ in subsequent NPS R-467
experiments. The large and small cells were seeded in six well
plates and cultured in the standard medium supplemented with
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rising [Ca2+]o from 0 to 12.5 mM CaCl2. Cell counts were
performed on days 1st and 4th after treatments. Calcium induced
cell growth in both large and small UCM-MSC lines in a dose-
dependent manner. This effect was observed at day 4th (Fig 1 A,B)
after treatment whereas no effect was found at day 1st (data not
shown). Given that in both cell lines the rising phase was
comprised between 0 and 5 mM CaCl2 and the maximal response
was observed at 5, 7.5 and 10 mM, subsequent experiments were
performed at 2.5 mM CaCl2 which was considered as EC50.
External calcium concentration in the present study was actually
either 0.37 or 2.87 mM Ca2+. Infact, standard medium was
supplemented with 10% FCS and, since average Ca2+
concentration in FCS is around 14.6 mg/dL, thus 3.7 mM [47],
Ca2+ concentration in our standard medium (10% FCS) was
around 0.37 mM. When additional 2.5 mM Ca2+ was included,
final Ca2+ concentration was 2.87 mM (0.37+2.5 = 2.87).
For the kinetic study, aimed to obtain growth curves (which
provide indication of cell growth rate) and doubling time (DT,
indicative of the proliferation rate), large and small cell lines at P5
were used. Cells were grown in four different culture conditions: 1)
control (CTRL): standard medium as described above; 2) higher
external calcium (2.5 mM CaCl2): standard medium plus 2.5 mM
CaCl2; 3) agonist (2.5 mM+R-467): standard medium plus
2.5 mM CaCl2 and 3 mM NPS R-467 added for the first
24 hours; 4) antagonis/agonist (2.5 mM+2390+R-467): standard
medium plus 2.5 mM CaCl2 and 3 mM NPS R-467, added for the
initial 24 hours. In these samples, before CaSR agonist addition,
cells were preincubated for 30 min with 10 mM NPS 2390. Except
for the CTRL wells, CaCl2, NPS R-467 and NPS 2390 were
added 72 hours after culture starting (cells seeding time). After
24 hours of incubation with tested compounds, culture medium
was replaced with standard expansion medium in CTRL wells
while medium with additional 2.5 mM CaCl2 in all other culture
conditions. Cells of each well were detached by using 0.05%
trypsin/0.02% EDTA in PBS and were counted, by dilution (1:1)
in Trypan blue, with Burker’s chamber.
For growth curves, the large and small cells were seeded in all
six wells of four culture plates (one for each culture condition) and
cell counts were performed in six different days, every two to three
days. Cells were counted at P5, on days: 1st, 4th, 7th, 9th, 11th, 14th
after treatments. The Student’s t-test was used to evaluate
statistical significances and values with P,0.05 were considered
as statistically different.
For DT calculation, cells were seeded, at the density of 1000
cell/cm2, in the first well of a six well plate, counted every
48 hours and re-seeded in the next well of the same plate at the
same density (1000 cell/cm2) to the end of the treatment. The DT
data were calculated by using the following formula: CD = ln(Nf/
Ni)/ln 2 and DT=CT/CD, where DT is the cell-doubling time,
CD is the cell-doubling number, and CT is the cell culture time.
The proliferation rate was calculated from each passage, where Nf
is the final number of cells and Ni the initial number of cells. For
DT calculation, cells were counted from P5 to P8.
Experiment 2a: Effects of high external calcium
concentration and the calcimimetic NPS R-467 on CaSR
transcript relative abundance in equine UCM-
MSCs. CaSR expression was evaluated on both large and
small cell lines on day 4th after treatment. At mRNA level, the
study was performed by comparative Real Time PCR. The
amplification of HPRT1 mRNA allowed us to assess the suitability
of the used total mRNA extraction method and the presence of
total mRNA as an endogenous control. Ct values of HPRT1 were
used to normalize the expression levels of the target gene in all
examined samples in both cell lines. Ovarian mural granulosa cells
were used as positive controls, as CaSR expression was previously
demonstrated in these cells [59]. The Student’s t-test was used to
evaluate the statistical significance of the results. Values with
P,0.05 were considered as statistically different.
Experiment 2b: Effects of high external calcium
concentration and the calcimimetic NPS R-467 on CaSR
protein expression and subcellular localization in equine
UCM-MSCs. At protein level, CaSR expression and subcellular
localization were evaluated by immunofluorescence and confocal
microscopy. Groups of 40 to 44 cells were analyzed for each
experimental condition. The statistical significance of the results
expressed as rates of cells showing prevailing cytoplasmic or
cortical CaSR labeling was evaluated by the Chi-square test with
the Yates correction for continuity. Proportion of cells showing
prevailing cytoplasmic or pericortical CaSR labeling were
compared between each treatment group and controls. Values
with P,0.05 were considered to be significantly different.
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